专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1990005541A1 IMMUNOTHERAPY INVOLVING CD28 STIMULATION 审中-公开
标题翻译：涉及CD28刺激的免疫治疗
公开(公告)号：WO1990005541A1
公开(公告)日：1990-05-31
申请号：PCT/US1989005304
申请日：1989-11-22
申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN , BRISTOL-MYERS SQUIBB COMPANY
发明人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN , BRISTOL-MYERS SQUIBB COMPANY , THOMPSON, Craig, B. , JUNE, Carl, H. , LEDBETTER, Jeffrey, A. , LINDSTEN, Tullia
IPC分类号： A61K39/395
CPC分类号： A61K39/02 , A61K35/17 , A61K38/00 , A61K2039/505 , A61K2039/5158 , C07K14/70521 , C07K16/00 , C07K16/2806 , C07K16/2809 , C07K16/2812 , C07K16/2815 , C07K16/2818 , C07K16/2833 , C07K16/2866 , C07K16/289 , C07K16/2896 , C07K2317/24 , C07K2317/54 , C07K2317/74 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/51 , C12N2501/515
摘要： A method of immunotherapy stimulates the T cell CD28 surface molecule to enhance T cell proliferation and increase overall lymphokine levels or to increase cellular production of human TH1 lymphokines or both. The method is selective for the induction of activated T cell mediated immune responses and enhances immune function even in the presence of immunosuppressants.
摘要翻译：免疫治疗的方法刺激T细胞CD28表面分子增强T细胞增殖并增加总淋巴细胞因子水平或增加人TH1淋巴因子或两者的细胞产生。该方法对于诱导活化的T细胞介导的免疫应答是有选择性的，即使在免疫抑制剂的存在下也增强免疫功能。

2. 发明申请

WO1998024411A2 METHOD FOR ORAL ADMINISTRATION OF BUSPIRONE 审中-公开
标题翻译：伯普林酮口服药物治疗方法
公开(公告)号：WO1998024411A2
公开(公告)日：1998-06-11
申请号：PCT/US1997019929
申请日：1997-11-06
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , SALAZAR, Daniel, E.
IPC分类号： A61K09/00
CPC分类号： A61K31/505 , A61K31/495 , A61K2300/00
摘要： An improved method for orally administering buspirone to a human subject wherein the bioavailability of buspirone is increased and its elimination, metabolite formation, and variability of these pharmacokinetic parameters is decreased, the improvement comprises the concurrent administration of a sufficient amount of nefazodone to effect these pharmacokinetic changes for orally administered buspirone.
摘要翻译：一种改进的方法用于将人螺旋体口服给予人类对象，其中丁螺环酮的生物利用度增加，并且其消除，代谢物形成和这些药代动力学参数的变异性降低，改善包括同时给予足量的奈法唑酮以实现这些药代动力学口服丁螺环酮的变化。

3. 发明申请

WO1998020931A1 DEVICES AND METHODS FOR APPLYING A MIXTURE OF TWO OR MORE LIQUID COMPONENTS TO FORM A BIOMATERIAL 审中-公开
标题翻译：用于将两种或更多液体组分的混合物用于形成生物体的装置和方法
公开(公告)号：WO1998020931A1
公开(公告)日：1998-05-22
申请号：PCT/US1997020653
申请日：1997-11-14
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , HOLM, Niels, Erik , LINNEBJERG, Steven , CORNWELL, Richard
IPC分类号： A61M31/00
CPC分类号： A61B17/00491 , A61B2017/00495 , A61M35/00 , B05B7/08 , B05B7/0876
摘要： Novel methods and devices which provide enhanced mixing, and application of two liquid components to form a biomaterial with minimized aerosols, are achieved using airflow rates below about 1.25 liters/minute in combination with a ratio of airflow to total liquid flow of from about 150:1 up to about 1500:1. Preferably the airflow is below about 1 liter/minute, and the ratio of airflow to total liquid flow is from about 200:1 to about 1200:1. The parameters are ideally suited for the spray application of components which form a surgical sealant, e.g., a fibrin sealant. Also a part of the present invention is novel application methods for biomaterial, e.g., surgical sealant, components at liquid flows below 1.9 ml/minute, novel methods involving the mixing of such components on the exit surface of a spray tip (14), or nozzle, novel spray tips (14), biomaterial applicators, and methods for making such applicators.
摘要翻译：使用低于约1.25升/分钟的气流速率结合两个液体组分以形成具有最小气溶胶的生物材料的新方法和装置，结合气流与总液体流量的比例为约150:1， 1到1500：1。优选地，气流低于约1升/分钟，并且气流与总液体流量的比率为约200:1至约1200:1。这些参数非常适用于喷雾施用形成外科密封剂的组分，例如纤维蛋白封闭剂。本发明的另一部分是用于生物材料的新型应用方法，例如手术密封剂，液体流速低于1.9ml /分钟的组分，涉及在喷嘴（14）的出口表面上混合这些组分的新方法，或喷嘴，新型喷嘴（14），生物材料施加器以及制造这种涂敷器的方法。

4. 发明申请

WO1998012996A1 IMPROVED WOUND DRESSING 审中-公开
标题翻译：改进的连衣裙
公开(公告)号：WO1998012996A1
公开(公告)日：1998-04-02
申请号：PCT/US1997017140
申请日：1997-09-22
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , KADASH, Marjory, A. , MARSH, Thomas, A. , SMITH, Salina
IPC分类号： A61F05/00
CPC分类号： A61L15/46 , A61F13/023 , A61F13/42 , A61L15/42 , A61L15/60 , A61L2300/404 , A61L2300/412
摘要： An improved wound dressing (10) is provided which comprises a backing layer (20) bearing a reference marking (25), a hydrocolloid layer (30), and a release layer (40). The hydrocolloid (30) swells in use. This swelling can be seen or felt through the backing layer (20). When the swelling extends to or beyond the reference marking (25), the dressing (10) should be changed to prevent leaking. Thus, the dressing (10) can be left in place for as long as possible, but not so long as to damage the underlying skin.
摘要翻译：提供了一种改进的伤口敷料（10），其包括具有参考标记（25），水胶体层（30）和脱模层（40）的背衬层（20）。水胶体（30）在使用中膨胀。可以通过背衬层（20）看到或感觉到这种膨胀。当膨胀延伸至或超过参考标记（25）时，应改变敷料（10）以防止泄漏。因此，敷料（10）可以留在适当的位置，尽可能长，但不会损坏下面的皮肤。

5. 发明申请

WO1998011907A1 PEPTIDE INHIBITORS OF NUCLEAR PROTEIN TRANSLOCATION HAVING NUCLEAR LOCALIZATION SEQUENCES AND METHODS OF USE THEREOF 审中-公开
标题翻译：具有核定位序列的核蛋白转录肽抑制剂及其使用方法
公开(公告)号：WO1998011907A1
公开(公告)日：1998-03-26
申请号：PCT/US1997016217
申请日：1997-09-15
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , NADLER, Steven, G. , CLEAVELAND, Jeffrey, S. , BLAKE, James , HAFFAR, Omar, K.
IPC分类号： A61K38/02
CPC分类号： C07K14/4703 , A61K38/00 , A61K45/06 , C07K2319/09 , C07K2319/10
摘要： Novel polypeptide inhibitors of cytoplasmic protein nuclear translocation are disclosed. The inhibitors are comprised of a signal sequence and at least two nuclear localization sequences. The polypeptides are useful as immunosuppression, antiviral and antitumor agents.
摘要翻译：公开了细胞质蛋白核易位的新型多肽抑制剂。抑制剂由信号序列和至少两个核定位序列组成。多肽可用作免疫抑制，抗病毒和抗肿瘤剂。

6. 发明申请

WO1998007433A1 CYTOTOXIC AMINO SUGAR AND RELATED SUGAR DERIVATIVES OF INDOLOPYRROLOCARBAZOLES 审中-公开
标题翻译： CYPOTOXIC AMINO糖及其相关糖衍生物
公开(公告)号：WO1998007433A1
公开(公告)日：1998-02-26
申请号：PCT/US1997014738
申请日：1997-08-21
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , SAULNIER, Mark, George , BALASUBRAMANIAN, Neelakantan , FRENNESSON, David, Bertil , ST. LAURENT, Denis, R. , LANGLEY, David, R.
IPC分类号： A61K31/70
CPC分类号： C07H17/02 , Y02P20/582
摘要： The present invention concerns novel amino sugar and related sugar derivatives of indolopyrrolocarbazoles, their use as antitumor agents, and pharmaceutical formulations.
摘要翻译：本发明涉及吲哚吡咯并唑的新型氨基糖和相关糖衍生物，它们作为抗肿瘤剂的用途和药物制剂。

7. 发明申请

WO1998004565A1 SOLVENT EXTRACTION OF 3-HYDROXYMETHYLCEPHALOSPORINS 审中-公开
标题翻译：溶剂萃取3-羟基甲基硬脂酰胺
公开(公告)号：WO1998004565A1
公开(公告)日：1998-02-05
申请号：PCT/US1997012194
申请日：1997-07-14
申请人： BRISTOL-MYERS SQUIBB COMPANY , LIM, Gary, M., F. , ROUBIE, John, M. , AUDIA, Vicki, H.
发明人： BRISTOL-MYERS SQUIBB COMPANY
IPC分类号： C07D501/60
CPC分类号： C07D501/00
摘要： The cephalosporin intermediate, desacetyl 7-glutaryl ACA, is obtained in the form of a concentrated aqueous solution from an aqueous solution containing said intermediate in less concentrated form by solvent extraction using cyclohexanone followed by back-extraction into water. The concentrated aqueous solution of intermediate is in a form which can be used for economical production of 7-ACA using known procedures.
摘要翻译：头孢菌素中间体脱乙酰基7-戊二酸ACA以浓缩水溶液的形式从含有较低浓度形式的中间体的水溶液形式通过溶剂萃取使用环己酮，然后反萃取到水中而获得。中间体的浓缩水溶液是可以用于使用已知方法经济地生产7-ACA的形式。

8. 发明申请

WO1998004135A1 DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS 审中-公开
标题翻译：二苯醚作为钾通道调节剂
公开(公告)号：WO1998004135A1
公开(公告)日：1998-02-05
申请号：PCT/US1997014352
申请日：1997-07-30
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , ROMINE, Jeffrey, L. , MARTIN, Scott, W. , HEWAWASAM, Piyasena , MEANWELL, Nicholas, A. , GRIBKOFF, Valentin, K. , STARRETT, John, E., Jr.
IPC分类号： A01N43/653
CPC分类号： C07D263/58 , C07D233/64 , C07D233/70 , C07D233/76 , C07D235/12 , C07D249/12 , C07D249/14 , C07D271/113 , C07D413/10
摘要： Novel compounds of formula (1) are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels, wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R , R and R each are independently selected from hydrogen, halogen, OH, CF3, NO2, or (a); provided R is not hydrogen; and when R and R are hydrogen, R may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; R and R each are independently selected form hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and R and R each are independently hydrogen; C1-4 alkyl; or R and R , taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.
摘要翻译：式（1）的新型化合物可用于治疗对大电导钙激活钾通道的开放物起反应的病症，其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a，R b和R c各自独立地选自氢，卤素，OH，CF 3，NO 2或（a）; 条件是R c不是氢; 当R a和R b为氢时，R c可以是选自咪唑-1-基，吗啉代甲基，N-甲基咪唑-2-基和吡啶-2-基的杂环部分，基; R d和R e各自独立地选自氢，卤素，CF 3，NO 2或咪唑-1-基; m，n和p各自独立地选自0或1的整数; 和R f和R g各自独立地为氢; C 1-4烷基; 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪，吗啉，硫代吗啉，N-苄基哌嗪和咪唑啉酮的杂环部分。

9. 发明申请

WO1998003551A1 CD6 LIGAND 审中-公开
公开(公告)号：WO1998003551A1
公开(公告)日：1998-01-29
申请号：PCT/US1997012511
申请日：1997-07-17
申请人： DUKE UNIVERSITY , BRISTOL-MYERS SQUIBB COMPANY
发明人： DUKE UNIVERSITY , BRISTOL-MYERS SQUIBB COMPANY , HAYNES, Barton, F. , ARUFFO, Alejandro , PATEL, Dhavalkumar , BOWEN, Michael, A. , MARQUARDT, Hans , SIADAK, Anthony, W.
IPC分类号： C07K16/18
CPC分类号： C07K14/705 , A61K38/00 , C07K14/70503 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K2319/00 , C07K2319/30 , G01N33/68 , G01N2333/70503
摘要： The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.
摘要翻译：本发明一般涉及CD6，特别是涉及存在于胸腺上皮细胞，单核细胞，活化的T细胞和多种其他细胞类型的表面上的CD6配体。本发明还涉及抑制CD6和CD6配体相互作用的方法，以及筛选化合物抑制该相互作用的能力的方法。本发明还涉及对CD6配体特异性的抗体及其结合片段。

10. 发明申请

WO1998003174A1 METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS 审中-公开
标题翻译：用于治疗具有使用MTP抑制剂的高LDL要求的肿瘤的方法
公开(公告)号：WO1998003174A1
公开(公告)日：1998-01-29
申请号：PCT/US1997012158
申请日：1997-07-14
申请人： BRISTOL-MYERS SQUIBB COMPANY
发明人： BRISTOL-MYERS SQUIBB COMPANY , FIRESTONE, Raymond, A.
IPC分类号： A61K31/445
CPC分类号： A61K45/06 , A61K31/00 , A61K31/4468 , A61K31/453 , A61K31/4535 , A61K31/454
摘要： A method is provided for treating hematologic tumors and solid tumors, including certain types of leukemias and metastatic tumors, having high LDL requirements employing a delipidating agent such as an MTP inhibitor to substantially reduce LDL blood levels. In addition, a method is provided for treating tumors of the above types having high LDL requirements, especially hematologic tumors such as certain leukemias, employing a delipidating compound to substantially remove native LDL, and then administering a cytotoxic agent carried in reconstituted LDL.
摘要翻译：提供了一种用于治疗血液肿瘤和实体瘤的方法，包括某些类型的白血病和转移性肿瘤，具有高LDL需求，使用脱脂剂如MTP抑制剂以显着降低LDL血液水平。此外，提供了一种用于治疗具有高LDL要求的上述类型的肿瘤的方法，特别是血液学肿瘤例如某些白血病，使用去脂化合物基本上除去天然的LDL，然后给予重组的LDL中携带的细胞毒性剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式